Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate (NASDAQ:TRVI)
Trevi TherapeuticsTrevi Therapeutics(US:TRVI) Seeking Alpha·2025-11-14 02:22

根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息 无法完成新闻解读任务 [1]